GlassScriptPhysician profile
Andrea Gillon
NPI 1952799850
$3,378.60
in general payments reported to CMS, 2019-2025
25 companies · $973 in 2025
The $973 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $414 · 2022: $164 · 2023: $942 · 2024: $885 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $421.65 | 2023-2025 | Ultomiris, Soliris |
| Tg Therapeutics, INC. | $360.08 | 2023-2025 | |
| Argenx US, INC. | $255.68 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Astrazeneca Pharmaceuticals LP | $252.47 | 2021-2024 | Saphnelo |
| Genentech USA, INC. | $221.58 | 2021-2025 | Xolair, Ocrevus Zunovo, Ocrevus |
| Abbvie INC. | $209.59 | 2021-2025 | |
| Grifols USA, LLC | $195.14 | 2022-2025 | Gamunex-C |
| Daiichi Sankyo INC. | $174.58 | 2021-2024 | Injectafer |
| Janssen Biotech, INC. | $171.07 | 2024-2025 | Stelara |
| Glaxosmithkline, LLC. | $145.46 | 2021-2024 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $140.11 | 2021-2025 | Hyqvia, Entyvio |
| Eisai INC. | $139.55 | 2023-2024 | |
| Lilly USA, LLC | $137.12 | 2024 | Omvoh |
| Alnylam Pharmaceuticals INC. | $104.72 | 2023-2025 | Amvuttra |
| Genzyme Corporation | $103.98 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $57.28 | 2023 | Vyepti |
| Sanofi-Aventis U.S. LLC | $55.73 | 2024 | |
| Organon LLC | $50.98 | 2023-2025 | Renflexis, Ontruzant |
| Amgen INC. | $49.30 | 2021-2024 | Evenity, Prolia |
| Janssen Scientific Affairs, LLC | $24.94 | 2025 | |
| Biogen, INC. | $24.86 | 2021 | |
| Biomarin Pharmaceutical INC. | $23.89 | 2021 | |
| Pfizer INC. | $22.92 | 2021 | |
| Pharmacosmos Therapeutics INC. | $20.90 | 2024 | Monoferric |
| Alkermes, INC. | $15.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Gillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.